

This Referring Physician Email Template is provided to assist you in educating your referral base on eXciteOSA®, a new FDA authorized daytime therapy for the reduction of mild obstructive sleep apnea and snoring.

Dear Dr [Name]:

Meet eXciteOSA®, the first FDA authorized daytime therapy for patients with mild obstructive sleep apnea (OSA) or snoring. eXciteOSA® is a user-controlled neuromuscular electrical stimulator (NMES). The electrical current has defined frequencies to stimulate and improve muscle function of the tongue. By improving the endurance of these muscles, the upper airway becomes trained to remain open during sleep, thereby reducing snoring and improving sleep quality.



How it works:

1. The mouthpiece is attached to the control unit and then placed in the mouth. It is controlled by the eXciteOSA® app.
2. The app activates electrodes in the mouthpiece via the control unit and electrical pulses stimulate the tongue muscle.
3. The app enables patients to monitor their usage as well as enables you to communicate with the patient directly via HIPAA-compliant cloud-based monitoring.

eXciteOSA® therapy is used for 20 minutes, one time each day for 6 weeks, and only twice per week thereafter.

Clinically proven results

When used for 20 minutes, one time each day for 6 weeks, eXciteOSA® has been clinically proven to improve quality of sleep by significantly reducing mild obstructive sleep apnea and snoring.

Objective improvement in mild OSA with the use of eXciteOSA®

In a recent study of which 79% of patients responded to therapy, the following improvements were recorded:¹

- 52% reduction in AHI¹
- 50% reduction in ODI¹
- 3.9 point reduction in ESS Score¹

Improvement in snoring with the use of eXciteOSA®

- Objective snoring: Patients achieved an average reduction in snoring time of 41% at >40dB¹
- Subjective snoring: Patient bed partners reported an average snoring reduction of 39%¹

Take the first step in learning more on how eXciteOSA® may be an effective therapy option for your patients with mild OSA and snoring.

Request more product information or a product demonstration here [link to your website/call a phone #].

REFERENCES

1. eXciteOSA® White Paper (2020). Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI) <15 n=65) completed the trial. Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPAT® night sleep studies before and after the use of the device. An intra- oral tongue stimulator device was used for 20 mins, once a day for 6-week period. (Internal publication by SMT for educational purposes and submission.)